[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564519":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":170,"collaborators":20,"id":172,"slug":173,"hasResults":174,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":20,"eligibilityCriteria":178,"healthyVolunteers":174,"sex":179,"minAge":180,"maxAge":20,"enrollmentInfo":181,"targetDuration":20,"studyType":184,"phases":185,"briefSummary":188,"conditions":189,"keywords":191,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":203},{"fullName":5,"class":6},"Deciphera Pharmaceuticals, LLC","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"DCC-3009 Module A","EXPERIMENTAL","Participants will receive DCC-3009 in 28 day cycles in Module A Part 1 dose escalation and Part 2 dose expansion.",[13],"Drug: DCC-3009",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","DCC-3009","Administered orally",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Clinical Team","STUDY_DIRECTOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","888-724-3274","clinicaltrials@deciphera.com",[31,43,54,69,84,98,112,126,141,155],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":20,"geoPoint":20,"contacts":39},"HonorHealth","RECRUITING","Scottsdate","Arizona","85258","United States","US",[40],{"name":41,"role":27,"phone":20,"phoneExt":20,"email":42},"Program Management","hriprograms@honorhealth.com",{"facility":44,"status":33,"city":45,"state":46,"zip":47,"country":37,"countryCode":38,"cosmosGeoPoint":48,"geoPoint":53,"contacts":20},"UC San Diego Moores Cancer Center","La Jolla","California","92093",{"type":49,"coordinates":50},"Point",[51,52],-117.2742,32.84727,{"lat":52,"lon":51},{"facility":55,"status":33,"city":56,"state":57,"zip":58,"country":37,"countryCode":38,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"University of Colorado Anschutz Medical Campus","Aurora","Colorado","80045",{"type":49,"coordinates":60},[61,62],-104.83192,39.72943,{"lat":62,"lon":61},[65],{"name":66,"role":27,"phone":67,"phoneExt":20,"email":68},"Steven Sares","303-724-9889","steven.sares@cuanschutz.edu",{"facility":70,"status":33,"city":71,"state":72,"zip":73,"country":37,"countryCode":38,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Mayo Clinic Florida","Jacksonville","Florida","32224",{"type":49,"coordinates":75},[76,77],-81.65565,30.33218,{"lat":77,"lon":76},[80],{"name":81,"role":27,"phone":82,"phoneExt":20,"email":83},"Caroline Teeter","904-953-5141","teeter.caroline@mayo.edu",{"facility":85,"status":33,"city":86,"state":72,"zip":87,"country":37,"countryCode":38,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"University of Miami - Sylvester Comprehensive Cancer Center","Miami","33136",{"type":49,"coordinates":89},[90,91],-80.19366,25.77427,{"lat":91,"lon":90},[94],{"name":95,"role":27,"phone":96,"phoneExt":20,"email":97},"Leah Anton, ARNP","305-243-2529","lxa712@med.miami.edu",{"facility":99,"status":33,"city":100,"state":101,"zip":102,"country":37,"countryCode":38,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Dana Farber Cancer Institute","Boston","Massachusetts","02215",{"type":49,"coordinates":104},[105,106],-71.05977,42.35843,{"lat":106,"lon":105},[109],{"name":110,"role":27,"phone":111,"phoneExt":20,"email":20},"Research Nurse","617-632-5204",{"facility":113,"status":33,"city":114,"state":115,"zip":116,"country":37,"countryCode":38,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"START Midwest","Grand Rapids","Michigan","49546",{"type":49,"coordinates":118},[119,120],-85.66809,42.96336,{"lat":120,"lon":119},[123],{"name":124,"role":27,"phone":20,"phoneExt":20,"email":125},"Hope Team","hopeteam@startresearch.com",{"facility":127,"status":33,"city":128,"state":129,"zip":130,"country":37,"countryCode":38,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"Mayo Clinic Rochester","Rochester","Minnesota","55905",{"type":49,"coordinates":132},[133,134],-92.4699,44.02163,{"lat":134,"lon":133},[137],{"name":138,"role":27,"phone":139,"phoneExt":20,"email":140},"Jordan Meyers","507-284-2030","Meyers.jordan@mayo.edu",{"facility":142,"status":33,"city":143,"state":143,"zip":144,"country":37,"countryCode":38,"cosmosGeoPoint":145,"geoPoint":149,"contacts":150},"Memorial Sloan Kettering Cancer Center","New York","10065",{"type":49,"coordinates":146},[147,148],-74.00597,40.71427,{"lat":148,"lon":147},[151],{"name":152,"role":27,"phone":153,"phoneExt":20,"email":154},"Ping Chi, MD","646-888-4166","chip@mskcc.org",{"facility":156,"status":33,"city":157,"state":158,"zip":159,"country":37,"countryCode":38,"cosmosGeoPoint":160,"geoPoint":164,"contacts":165},"Vanderbilt University-Ingram Cancer Center","Nashville","Tennessee","37232",{"type":49,"coordinates":161},[162,163],-86.78444,36.16589,{"lat":163,"lon":162},[166],{"name":167,"role":27,"phone":168,"phoneExt":20,"email":169},"Vanderbilt-Ingram Cancer Center Clinical Trials Office (CTO)","800-811-8480","CTIP@VUMC.ORG",{"type":171,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100564519","phase-1-a-master-protocol-to-evaluate-dcc-3009-in-gastrointestinal-stromal-tumor-gist-100564519",false,"NCT06630234","A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)","A Master Protocol for the Multi-cohort, Open-label, Phase 1\u002F2 Study of DCC-3009 in Participants With Gastrointestinal Stromal Tumor (GIST)","Inclusion Criteria:\n\nModule A Part 1 (Escalation):\n\n* Any participant with histologically or cytologically confirmed advanced\u002Funresectable or metastatic GIST with documented KIT or platelet-derived growth factor receptor alpha (PDGFRA) mutation, who has progressed on or was intolerant to at least 1 approved tyrosine kinase inhibitor (TKI) regimen in the advanced\u002Fmetastatic setting\n* Have at least 1 measurable lesion as defined by mRECIST, v1.1\n* Have Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1\n* Adequate organ function, bone marrow function, and electrolytes\n* All participants agree to comply with the contraception requirements\n* Have a life expectancy of more than 3 months\n\nExclusion Criteria:\n\n* Received systemic anticancer therapy or radiotherapy within 14 days prior to first dose of study drug\n* Prior or concurrent malignancy that requires treatment or is expected to require treatment for active cancer\n* Has known active central nervous system (CNS) metastases or an active primary CNS cancer\n* History or presence of clinically relevant cardiovascular abnormalities\n* Major surgery within 28 days of the first dose of study drug\n* Had systemic arterial thrombotic or embolic events within 6 months prior to the first dose of study drug\n* Had venous thrombotic events (e.g., deep vein thrombosis) or venous thrombotic embolic events (e.g., pulmonary embolism) within 1 month prior to the first dose of study drug\n* Known allergy or hypersensitivity to any component of the study drug\n* Malabsorption syndrome or other illness that could affect oral absorption\n* Any other clinically significant comorbidities","ALL","18 Years",{"count":182,"type":183},120,"ESTIMATED","INTERVENTIONAL",[186,187],"PHASE1","PHASE2","The purpose of this Phase 1\u002F2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer therapies. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). Participants will be treated in 28-day treatment cycles with an estimated duration of up to 2 years.",[190],"Gastrointestinal Stromal Tumor (GIST)",[192,193],"PDGFRA mutations","KIT mutations","2026-02-03",{"date":196,"type":197},"2026-02-05","ACTUAL",{"date":199,"type":197},"2024-12-10",{"date":201,"type":183},"2028-05",{"name":5,"class":6},10]